Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics is benefiting from a major reimbursement inflection as Medicare has started paying the full expected rate of $1,938 per EsoGuard test, far above the Q2'26 realized ASP of about $530, which materially improves unit economics and derisks commercialization. The company’s first LBM win with Concert, adoption by three health plans, and active dialogue with large commercial payors add third-party validation for a novel, non-invasive test aimed at a large, underpenetrated GERD screening market with an estimated $2 billion domestic opportunity and ~$20 billion+ potential for U.S. men alone. A $15 million financing also strengthens the balance sheet, while the 2,770 tests processed in Q2 and roughly $45 million in potential test revenue backlog suggest meaningful operating leverage if reimbursement and coverage continue to expand.

Lucid Diagnostics is challenged by an unproven commercial model, as EsoGuard and EsoCheck are still generating only modest revenue while broader adoption depends on payer traction, clinician awareness, and expansion of its sales force. The most important near-term risk is reimbursement, because its attractive Medicare payment rate is not yet active or billable until Palmetto GBA’s MolDx issues an LCD, and there is no certainty on timing or approval. The bearish view is further reinforced by balance sheet, clinical utility, intellectual property, competition, and manufacturing risks, all of which could hinder commercialization and limit revenue growth.